Replies to post #682336 on NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Zadie, I may be wrong but my guess is that after approval,
the utilization of temodar for patients receiving DCVax-l
will become more infrequent for those with methylated nGBM
and will not be used at all for those with unmethylated nGBM.

And yes, I believe that it was Flipper who first suggested that
patients receiving DCVax-l, should not be treated with
temozolamide.

[flipper44]

Doesn’t matter who thought of it first.

My thought was/is one short course of tmz, maybe four weeks, (because otherwise tmz inhibits t-cells & other immune cells) when tumor has/had methylated mgmt, followed by a normal course of DCVax-l therapy, followed by DCVax-l maintainance boosters.

With unmethylated mgmt, maybe no TMZ, and receive DCVax-l therapy, followed by DCVax-l maintainance boosters.

Of course there are many more things they are hoping to incorporate with DCVax-l, like add poly-iclc, plx3397 and perhaps CI.

I think even Dr. Stupp has come around to not necessarily giving tmz to unmethylated patients.

JMHO.